Two of the numbers on your standard lipid panel, when divided by each other, become one of the most useful pieces of information you can get from a basic blood draw. The TG/HDL ratio (triglycerides divided by HDL cholesterol) reflects whether your body is starting to lose its grip on sugar and whether your cholesterol is shifting toward the small, dense, plaque-building kind.
You can have a normal LDL number and still carry significant cardiometabolic risk if this ratio is high. That is why preventive cardiologists pay close attention to it: a number you already have on your last lab report can flag insulin resistance, fatty liver, and rising heart attack risk years before glucose, blood pressure, or LDL move out of range.
Across very large cohorts spanning the UK, China, Iran, and Korea, a higher TG/HDL ratio has consistently predicted future heart attacks, strokes, and cardiovascular death, even after accounting for standard risk factors. In the UK Biobank analysis of more than 400,000 adults, people with higher ratios had a clear, dose-dependent jump in cardiovascular events. A pooled analysis of 13 cohort studies covering more than 207,000 people found those in the highest TG/HDL category had 26 to 43 percent higher cardiovascular disease risk than those in the lowest.
In people who already have stable angina or established coronary disease, the ratio continues to predict major coronary events and plaque burden independently of LDL. A meta-analysis of patients with coronary artery disease found higher TG/HDL values were tied to more heart attacks, cardiovascular deaths, repeat procedures, and stent complications. This is part of what cardiologists call "residual risk": the danger that remains even when LDL has been driven down with a statin.
The TG/HDL ratio is one of the simplest available markers for insulin resistance, the underlying glitch in sugar handling that quietly precedes type 2 diabetes by years. In a study of middle-aged and elderly Taiwanese adults, a ratio above 2.20 identified insulin resistance with about 72 percent sensitivity and 65 percent specificity. In Argentine adults, the ratio matched a full metabolic syndrome diagnosis at flagging insulin-resistant individuals, while needing only two lab values instead of five.
In a 10-year Japanese cohort of more than 120,000 workers, the ratio outperformed LDL, HDL, or triglycerides alone at predicting who would develop type 2 diabetes. In older Chinese adults, each step up in the ratio raised diabetes risk independently of weight, blood pressure, and lipids. A 12-year Korean follow-up of community-dwelling adults aged 40 to 69 reached the same conclusion.
Higher TG/HDL also tracks closely with fat accumulation in the liver. In a U.S. population analysis, the ratio outperformed BMI, fasting glucose, and standard liver enzymes for identifying metabolic dysfunction-associated steatotic liver disease (MASLD, the modern name for non-alcoholic fatty liver). A cutoff of 0.80 caught about 75 percent of cases while correctly clearing 71 percent of healthy individuals. In children with non-alcoholic fatty liver, the ratio also independently predicted who already had liver fibrosis (scarring).
In advanced chronic kidney disease, higher TG/HDL is linearly tied to cardiovascular events and all-cause mortality and outperforms LDL when kidney function is poor. A separate study in IgA nephropathy (a common kidney disease) found higher ratios independently predicted worse renal survival and progression to end-stage kidney failure. A high ratio also tracks with increased albumin in the urine, an early sign of kidney damage, in the general Chinese population.
There is no single universally agreed cutpoint for the TG/HDL ratio. Optimal thresholds shift by age, sex, and ethnic group, and the absolute number depends on whether your lab measures triglycerides and HDL in mg/dL (common in the United States) or mmol/L (common elsewhere). The ranges below come from a multi-ethnic Brazilian cohort of about 15,700 adults (the ELSA-Brasil study) using the U.S. unit convention. They are useful orientation, not a universal target. Compare your results within the same lab over time for the most meaningful trend.
| Tier | Range (TG and HDL in mg/dL) | What It Suggests |
|---|---|---|
| Low risk (men) | Below 2.6 | Favorable insulin sensitivity and lipid profile |
| High risk (men) | 2.6 or higher | Increased risk of hypertension, diabetes, obesity, metabolic syndrome, insulin resistance |
| Low risk (women) | Below 1.7 | Favorable insulin sensitivity and lipid profile |
| High risk (women) | 1.7 or higher | Increased risk of hypertension, diabetes, obesity, metabolic syndrome, insulin resistance |
Source: ELSA-Brasil cohort (Lelis et al., 2021). Other studies have used different thresholds, including approximately 1.49 for predicting metabolic syndrome in elderly Chinese adults, around 2.20 for detecting insulin resistance in middle-aged and elderly Taiwanese adults, and 3.3 for metabolic syndrome in Korean adolescents.
What this means for you: the lower, the better, within reason. People in the bottom quartile in long-term cohorts had the lowest rates of diabetes, heart attack, and stroke. There is no published evidence of a level that is too low.
In adults 65 and older, the link between a high ratio and atherosclerotic cardiovascular disease weakens, and one analysis of nearly 35,000 older adults found a high ratio in this group could even associate with slightly lower atherosclerotic cardiovascular disease risk. This does not mean a high ratio becomes good with age. The ratio is a phenotype indicator: at younger ages, it primarily marks insulin resistance and atherogenic dyslipidemia, both of which drive disease. By age 65 and beyond, survival bias, competing causes of death, and the dominance of established disease change what a high or low number means. In midlife, treat this number as a meaningful early warning. In your 70s and beyond, interpret it alongside other markers and your overall health picture, not in isolation.
A single TG/HDL reading can be distorted by short-term factors that have nothing to do with your underlying biology:
Because triglycerides are biologically variable and HDL responds slowly to lifestyle changes, a single number is far less useful than the trajectory. The point of repeated testing is to catch a drift toward insulin resistance before any threshold is crossed and to confirm that an intervention is actually working in your body, not just on paper.
A reasonable cadence: get a baseline, retest in 3 to 6 months if you are making meaningful lifestyle or medication changes, then at least once a year for monitoring. If your ratio is trending up year over year, that signal matters even if you are still inside a reference range. Keep your testing within the same lab when possible, and try to keep fasting status and time of day consistent across draws.
An elevated TG/HDL ratio rarely warrants a panic response. It warrants a workup. The pattern of results around it tells you what is driving the number and what to do next.
Evidence-backed interventions that affect your TG/HDL Cholesterol level
TG/HDL Cholesterol is best interpreted alongside these tests.